HBK Sorce Advisory LLC Invests $2.26 Million in CVS Health Corporation $CVS

HBK Sorce Advisory LLC bought a new stake in CVS Health Corporation (NYSE:CVS) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 22,836 shares of the pharmacy operator’s stock, valued at approximately $2,264,000.

Several other institutional investors have also bought and sold shares of CVS. Handelsbanken Fonder AB increased its stake in CVS Health by 83.6% in the 2nd quarter. Handelsbanken Fonder AB now owns 1,089,694 shares of the pharmacy operator’s stock valued at $112,729,000 after buying an additional 496,124 shares during the last quarter. State Street Corp boosted its stake in shares of CVS Health by 2.1% in the 4th quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock worth $4,776,182,000 after buying an additional 1,245,457 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of CVS Health by 0.3% in the fourth quarter. Legal & General Group Plc now owns 9,309,182 shares of the pharmacy operator’s stock valued at $738,777,000 after acquiring an additional 31,249 shares in the last quarter. Deutsche Bank AG increased its position in shares of CVS Health by 28.4% during the fourth quarter. Deutsche Bank AG now owns 4,666,495 shares of the pharmacy operator’s stock valued at $370,333,000 after acquiring an additional 1,031,998 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in shares of CVS Health by 13.7% during the first quarter. SG Americas Securities LLC now owns 1,228,069 shares of the pharmacy operator’s stock valued at $87,459,000 after acquiring an additional 147,827 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Sanford C. Bernstein boosted their price objective on CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 12th. Piper Sandler reaffirmed an “overweight” rating and set a $113.00 target price on shares of CVS Health in a research report on Monday, June 1st. Argus lifted their target price on CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a research note on Thursday, May 14th. Robert W. Baird set a $107.00 price target on shares of CVS Health in a report on Thursday, August 6th. Finally, Weiss Ratings upgraded shares of CVS Health from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 5th. Twenty-two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $106.75.

Insiders Place Their Bets

In other CVS Health news, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the transaction, the director owned 6,213,261 shares in the company, valued at $586,842,501.45. This trade represents a 24.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 3,372,000 shares of company stock worth $317,473,598 in the last three months. 0.85% of the stock is owned by company insiders.

CVS Health Price Performance

Shares of NYSE CVS opened at $97.09 on Monday. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. The stock has a fifty day simple moving average of $102.52 and a two-hundred day simple moving average of $88.26. CVS Health Corporation has a 1-year low of $67.42 and a 1-year high of $110.68. The firm has a market cap of $124.18 billion, a price-to-earnings ratio of 25.69, a price-to-earnings-growth ratio of 0.93 and a beta of 0.61.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.71. The firm had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The business’s revenue was up 7.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Analysts anticipate that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd were issued a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, July 23rd. This represents a $2.66 annualized dividend and a yield of 2.7%. CVS Health’s dividend payout ratio is 70.37%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.